MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dyskinesias"

  • 2022 International Congress

    Cognitive and Motor aspects of a Brazilian population with Parkinson´s disease and Impulse Control Disorders and/or Related Behaviors – an observational study.

    B. Veiga, C. da Silva, L. Barcelos, H. Ferraz, S. Silva, V. Borges (São Paulo, Brazil)

    Objective: We analysed if Impulse Control Disorders (ICDs) and/or Related Behaviors (RBs) were associated with levodopa-induced dyskinesia (LIDs) in Brazilian patients with Parkinson´s disease (PD)…
  • 2022 International Congress

    Home-based transcranial static magnetic field stimulation of the motor cortex for treating levodopa-induced dyskinesias in Parkinson’s disease

    M. Dileone, C. Ammann, V. Catanzaro, C. Pagge, R. Piredda, MHG. Monje, I. Navalpotro-Gómez, A. Bergareche, MC. Rodriguez-Oroz, L. Vela, F. Alonso-Frech, MJ. Catalán-Alonso, JA. Molina, N. López-Ariztegui, A. Oliviero, JA. Obeso, G. Foffani (Móstoles, Spain)

    Objective: To investigate the potential of transcranial static magnetic field stimulation (tSMS) as a non-pharmacological, non-invasive, home-based treatment to manage levodopa-induced dyskinesias (LIDs) in Parkinson’s…
  • 2022 International Congress

    Bitopertin, a GlyT1 inhibitor, attenuates the development of dyskinesia in the 6-OHDA-lesioned rat

    I. Frouni, W. Kang, D. Bédard, S. Belliveau, C. Kwan, A. Hamadjida, P. Huot (Montreal, Canada)

    Objective: To evaluate the effect of the glycine transporter 1 (GlyT1) inhibitor bitopertin at preventing dyskinesia development in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson’s…
  • 2022 International Congress

    Relationship between lesion topography and incidence of dyskinesias following focused ultrasound subthalamotomy.

    J. Máñez-Miró, R. Rodríguez-Rojas, J. Pineda-Pardo, M. Del álamo, R. Martinez-Fernandez, J. Obeso (Mostoles, Spain)

    Objective: To describe the relation between the topography of subthalamotomy by focused ultrasound (FUS) for the treatment of Parkinson’s disease (PD) (1), and the risk…
  • 2022 International Congress

    Clinical Outcomes and Disease Burden of Advanced Parkinson’s Disease Patients Treated with Oral Medication Vs. Device-Aided Therapies: Preliminary Results from the University of Florida Registry Analysis

    W. Hu, O. Ladhani, P. Kukreja, A. Ramirez-Zamora (Gainesville, USA)

    Objective: Compare real-world clinical outcomes of Parkinson’s disease (PD) patients with moderate/severe motor fluctuations and/or dyskinesia treated with oral medications compared to device-aided therapies. Background:…
  • 2022 International Congress

    Validation of the PD Home Diary for Assessment of Motor Fluctuations in Advanced Parkinson’s Disease

    M. Löhle, A. Bremer, F. Gandor, J. Timpka, P. Odin, G. Ebersbach, A. Storch (Rostock, Germany)

    Objective: To determine the validity of the Parkinson’s disease (PD) home diary for quantification of motor states in patients with advanced PD and motor fluctuations.…
  • 2022 International Congress

    Globus pallidus as a neurosurgical target in the management of levodopa-induced dyskinesias

    A. Simonyan, V. Tyurnikov, V. Poleshuk, A. Simonyan, A. Gushcha (Moscow, Russian Federation)

    Objective: Parkinson's disease (PD) is a neurodegenerative disorder characterized by the development of motor symptoms, as well as some non-motor changes. Symptomatic treatment of PD…
  • 2022 International Congress

    Movement disorders in pediatric anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis

    M. Jamoussi, H. Benrhouma, Z. Miladi, T. Ben Younes, H. Klaa, I. Kraoua, I. Ben Youssef, M. Ben Ahmed (Tunis, Tunisia)

    Objective: Our aim was to investigate clinical characteristics and evolution of movement disorders (MD) in pediatric anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis. Background: Movement disorders account for…
  • 2022 International Congress

    Determination of glycine transporter 1 levels with [3H]-NFPS binding in hemi-parkinsonian rats with L-DOPA induced dyskinesia

    I. Frouni, D. Bédard, E. Kim, S. Belliveau, C. Kwan, P. Huot (Montreal, Canada)

    Objective: To determine the distribution of the glycine transporter 1 (GlyT1) in brain areas implicated in parkinsonism and L-3,4-dihydroxyphenylalanine (L-DOPA) induced dyskinesia in the 6-hydroxydopamine…
  • 2022 International Congress

    Prevalence of Movement Disorders After Acute Stroke: a Large Prospective Cohort Stroke Study

    MS. Rocha, L. Alves, J. Tatsch, H. Bezerra, J. Freitas, I. Torres, J. de Paula, P. Marques, P. Matos (SAO PAULO, Brazil)

    Objective: To ascertain the prevalence of acute post-stroke movement disorders (PSMD) in a prospective cohort of acute stroke patients. Background: Post-stroke movement disorders can occur…
  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 44
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley